Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

The RESOLUTE consortium: unlocking SLC transporters for drug discovery

The Innovative Medicines Initiative Consortium RESOLUTE has started to develop tools and produce data sets to de-orphanize transporters in the solute carrier protein (SLC) superfamily, thereby lowering the barrier for the scientific community to explore SLCs as an attractive drug target class.
By
  1. Giulio Superti-Furga

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria; Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.

  2. Daniel Lackner

    1. †Deceased. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  3. Tabea Wiedmer

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  4. Alvaro Ingles-Prieto

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  5. Barbara Barbosa

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  6. Enrico Girardi

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  7. Ulrich Goldmann

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  8. Bettina Gürtl

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  9. Kristaps Klavins

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  10. Christoph Klimek

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  11. Sabrina Lindinger

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  12. Eva Liñeiro-Retes

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  13. André C. Müller

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  14. Svenja Onstein

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  15. Gregor Redinger

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  16. Daniela Reil

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  17. Vitaly Sedlyarov

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  18. Gernot Wolf

    1. CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

  19. Matthew Crawford

    1. Pfizer Worldwide Research, Development and Medical, Cambridge, USA.

  20. Robert Everley

    1. Pfizer Worldwide Research, Development and Medical, Cambridge, USA.

  21. David Hepworth

    1. Pfizer Worldwide Research, Development and Medical, Cambridge, USA.

  22. Shenping Liu

    1. Pfizer Worldwide Research, Development and Medical, Groton, USA.

  23. Stephen Noell

    1. Pfizer Worldwide Research, Development and Medical, Groton, USA.

  24. Mary Piotrowski

    1. Pfizer Worldwide Research, Development and Medical, Groton, USA.

  25. Robert Stanton

    1. Pfizer Worldwide Research, Development and Medical, Groton, USA.

  26. Hui Zhang

    1. Pfizer Worldwide Research, Development and Medical, Groton, USA.

  27. Salvatore Corallino

    1. Axxam SpA, Bresso, Italy.

  28. Andrea Faedo

    1. Axxam SpA, Bresso, Italy.

  29. Maria Insidioso

    1. Axxam SpA, Bresso, Italy.

  30. Giovanna Maresca

    1. Axxam SpA, Bresso, Italy.

  31. Loredana Redaelli

    1. Axxam SpA, Bresso, Italy.

  32. Francesca Sassone

    1. Axxam SpA, Bresso, Italy.

  33. Lia Scarabottolo

    1. Axxam SpA, Bresso, Italy.

  34. Michela Stucchi

    1. Axxam SpA, Bresso, Italy.

  35. Paola Tarroni

    1. Axxam SpA, Bresso, Italy.

  36. Sara Tremolada

    1. Axxam SpA, Bresso, Italy.

  37. Helena Batoulis

    1. Bayer AG, Leverkusen, Germany.

  38. Andreas Becker

    1. Bayer AG, Leverkusen, Germany.

  39. Eckhard Bender

    1. Bayer AG, Leverkusen, Germany.

  40. Yung-Ning Chang

    1. Bayer AG, Leverkusen, Germany.

  41. Alexander Ehrmann

    1. Bayer AG, Leverkusen, Germany.

  42. Anke Müller-Fahrnow

    1. Bayer AG, Leverkusen, Germany.

  43. Vera Pütter

    1. Bayer AG, Leverkusen, Germany.

  44. Diana Zindel

    1. Bayer AG, Leverkusen, Germany.

  45. Bradford Hamilton

    1. Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

  46. Martin Lenter

    1. Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

  47. Diana Santacruz

    1. Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

  48. Coralie Viollet

    1. Boehringer-Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany.

  49. Charles Whitehurst

    1. Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA.

  50. Kai Johnsson

    1. Max Planck Institute for Medical Research, Heidelberg, Germany.

  51. Philipp Leippe

    1. Max Planck Institute for Medical Research, Heidelberg, Germany.

  52. Birgit Baumgarten

    1. Novartis Pharma AG, Basel, Switzerland.

  53. Lena Chang

    1. Novartis Pharma AG, Basel, Switzerland.

  54. Yvonne Ibig

    1. Novartis Pharma AG, Basel, Switzerland.

  55. Martin Pfeifer

    1. Novartis Pharma AG, Basel, Switzerland.

  56. Jürgen Reinhardt

    1. Novartis Pharma AG, Basel, Switzerland.

  57. Julian Schönbett

    1. Novartis Pharma AG, Basel, Switzerland.

  58. Paul Selzer

    1. Novartis Pharma AG, Basel, Switzerland.

  59. Klaus Seuwen

    1. Novartis Pharma AG, Basel, Switzerland.

  60. Charles Bettembourg

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  61. Bruno Biton

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  62. Jörg Czech

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  63. Hélène de Foucauld

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  64. Michel Didier

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  65. Thomas Licher

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  66. Vincent Mikol

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  67. Antje Pommereau

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  68. Frédéric Puech

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  69. Veeranagouda Yaligara

    1. Sanofi Recherche et Développement, Chilly-Mazarin, France.

  70. Aled Edwards

    1. Structural Genomics Consortium, Toronto, Canada.

  71. Brandon J. Bongers

    1. Universiteit Leiden, Leiden, the Netherlands.

  72. Laura H. Heitman

    1. Universiteit Leiden, Leiden, the Netherlands.

  73. Ad P. IJzerman

    1. Universiteit Leiden, Leiden, the Netherlands.

  74. Huub J. Sijben

    1. Universiteit Leiden, Leiden, the Netherlands.

  75. Gerard J.P. van Westen

    1. Universiteit Leiden, Leiden, the Netherlands.

  76. Justine Grixti

    1. University of Liverpool, Liverpool, UK.

  77. Douglas B. Kell

    1. University of Liverpool, Liverpool, UK.

  78. Farah Mughal

    1. University of Liverpool, Liverpool, UK.

  79. Neil Swainston

    1. University of Liverpool, Liverpool, UK.

  80. Marina Wright-Muelas

    1. University of Liverpool, Liverpool, UK.

  81. Tina Bohstedt

    1. University of Oxford, Oxford, UK.

  82. Nicola Burgess-Brown

    1. University of Oxford, Oxford, UK.

  83. Liz Carpenter

    1. University of Oxford, Oxford, UK.

  84. Katharina Dürr

    1. University of Oxford, Oxford, UK.

  85. Jesper Hansen

    1. University of Oxford, Oxford, UK.

  86. Andreea Scacioc

    1. University of Oxford, Oxford, UK.

  87. Giulia Banci

    1. University of Vienna, Vienna, Austria.

  88. Claire Colas

    1. University of Vienna, Vienna, Austria.

  89. Daniela Digles

    1. University of Vienna, Vienna, Austria.

  90. Gerhard Ecker

    1. University of Vienna, Vienna, Austria.

  91. Barbara Füzi

    1. University of Vienna, Vienna, Austria.

  92. Viktoria Gamsjäger

    1. University of Vienna, Vienna, Austria.

  93. Melanie Grandits

    1. University of Vienna, Vienna, Austria.

  94. Riccardo Martini

    1. University of Vienna, Vienna, Austria.

  95. Florentina Troger

    1. University of Vienna, Vienna, Austria.

  96. Patrick Altermatt

    1. Vifor (International) AG, St Gallen, Switzerland.

  97. Cédric Doucerain

    1. Vifor (International) AG, St Gallen, Switzerland.

  98. Franz Dürrenberger

    1. Vifor (International) AG, St Gallen, Switzerland.

  99. Vania Manolova

    1. Vifor (International) AG, St Gallen, Switzerland.

  100. Anna-Lena Steck

    1. Vifor (International) AG, St Gallen, Switzerland.

  101. Hanna Sundström

    1. Vifor (International) AG, St Gallen, Switzerland.

  102. Maria Wilhelm

    1. Vifor (International) AG, St Gallen, Switzerland.

  103. Claire M. Steppan

    1. Pfizer Worldwide Research, Development and Medical, Groton, USA.

Access through your institution
Buy or subscribe

The solute carrier proteins (SLCs) comprise a superfamily of transporters controlling the import and export of molecules across membranes. With more than 450 members, SLCs are the largest family of transporters encoded by the human genome. Although some members are successful drug targets, such as glucose and neurotransmitter transporters, the vast majority of SLCs have not been exploited therapeutically. In fact, many SLCs are ‘orphans’ in terms of knowledge of their substrate specificity and biological function.

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 19, 429-430 (2020)

doi: https://doi.org/10.1038/d41573-020-00056-6

Acknowledgements

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777372. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

References

  1. Lin, L., Yee, S. W., Kim, R. B. & Giacomini, K. M. SLC transporters as therapeutic targets: emerging opportunities. Nat. Rev. Drug. Discov. 14, 543–560 (2015).

    Article  PubMed  Google Scholar 

  2. Luteijn, R.D. et al. SLC19A1 transports immunoreactive cyclic dinucleotides. Nature 573, 434–438 (2019).

    Article  PubMed  Google Scholar 

  3. Girardi E et al. A widespread role for SLC transmembrane transporters in resistance to cytotoxic drugs. Nat. Chem. Biol. https://doi.org/10.1038/s41589-020-0483-3 (2020).

  4. Karageorgis, G. et al. Chromopynones are pseudo natural product glucose uptake inhibitors targeting glucose transporters GLUT-1 and -3. Nat. Chem 10, 1103–1111 (2018).

    Article  PubMed  Google Scholar 

  5. Nolin, E. et al. Discovery of a ZIP7 inhibitor from a Notch pathway screen.Nat. Chem. Biol. 15, 179–188 (2019).

    Article  PubMed  Google Scholar 

Download references

Competing Interests

Although research of the RESOLUTE consortium is in the precompetitive space, the following authors are employed by companies as indicated in more detail by their affiliations: M.C., R.E., D.H., S.L., S.N., M.P., R.S., C.M.S., H.Z., S.C., A.F., M.I., G.M., L.R., F.S., L.S., M.S., P.T., S.T., H.B., A.B., E.B., Y.N.C., A.E., A.M.F., V.P., D.Z., B.H., M.L., D.S., C.V., C.W., B.B., L.C., Y.I., M.P., J.R., J.S., P.S., K.S., C.B., B.B., J.C., M.D., H.F., T.L., V.M., A.P., F.P., V.Y., P.A., C.D., F.D., V.M., A.L.S., H.S., M.W.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links